Study S002618

Postmarketing Clinical Study of Ipragliflozin - Long-term Study in Combination With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02291874
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 100
Start: 2014-10-08
Primary completion: 2016-07-07
Lead sponsor: Astellas Pharma Inc
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Ipragliflozin
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

HbA1c [at 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52-week]
Fasting plasma glucose [at 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52-week]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017965	Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study. Ishihara H, Diabetes therapy : research, treatment and education of diabetes and related disorders	2018	Other trial	PMID 29926400 DOI	cites ClinicalTrials.gov:NCT02291874; registry reference DERIVED:29926400